Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

To investigate recovery of olfactory function in patients treated with PEA-LUT oral supplements plus olfactory training versus olfactory training plus placebo.

Sniffin' Sticks assessments were used to test the patients at baseline and 90 days.

Why It Was Studied

Olfactory training is the only evidence-based treatment for post-viral olfactory dysfunction.

Smell disorders after SARS-CoV-2 infection have been attributed to neuroinflammatory events within the olfactory bulb and the central nervous system.

Who Took Part

Eligible subjects had prior COVID-19 and persistent olfactory impairment >6 months after follow-up SARS-CoV-2 negative testing, without prior history of olfactory dysfunction or other sinonasal disorders.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.

Running at several centres spread the Copper (Supplement) study over different clinics and patient groups.

Multicenter double-blinded randomized placebo-controlled clinical trial was held.

What Was Measured

Topics PubMed links to this paper include Amides, COVID-19, Dietary Supplements, Ethanolamines, Luteolin, Olfaction Disorders and Palmitic Acids.

The authors tagged it with the keywords SARS-CoV-2, anosmia, anti-inflammatory, coronavirus, hyposmia and olfactory dysfunction.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Current neuropharmacology), a journal based in United Arab Emirates.

More context: the Copper (Supplement) compound page, all human trials.